Ju Hun Lee
0000-0001-7222-0510
Publication & Citation Trends
Publications
0 total
Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma.
Cited by 11
Semantic Scholar
Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma OA
Cited by 13
Semantic Scholar
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas OA
Cited by 18
Semantic Scholar
Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience OA
Cited by 10
Semantic Scholar
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma OA
Cited by 9
Semantic Scholar
Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma
Cited by 0
Semantic Scholar
CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin OA
Cited by 1
Semantic Scholar
Research Topics
Biofuel production and bioconversion
(28)
Microbial Metabolic Engineering and Bioproduction
(18)
Advanced biosensing and bioanalysis techniques
(16)
Food composition and properties
(15)
Magnetic properties of thin films
(8)
Affiliations
Dongyang Mirae University
Gangneung–Wonju National University
Berkeley College
Hallym University
Hanseo University